María Victoria
Mateos Manteca
Profesora Titular de Universidad
Rabin Medical Center
Petaẖ Tiqwa, IsraelPublikationen in Zusammenarbeit mit Forschern von Rabin Medical Center (5)
2013
-
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 4, pp. 448-455
2011
-
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
European Journal of Haematology, Vol. 86, Núm. 5, pp. 372-384
-
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study
European Journal of Haematology, Vol. 86, Núm. 1, pp. 23-31
2010
2008
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
New England Journal of Medicine, Vol. 359, Núm. 9, pp. 906-917